Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 3, 2010Clinical Pharmacology & Therapeutics

Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1

View Full Paper
Ask AI
Bookmark
Share

Authors

EMElizabeth MigoyaSumitomo Dainippon Pharma (United States)RBRaynald BergeronUniversité de MontréalJMJutta MillerNorthwestern University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Migoya et al. (2010) studied this question.

synapsesocial.com/papers/6a72c30cce524a4339c592bfhttps://doi.org/10.1038/clpt.2010.184
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes2007 · 491 citations
  2. 2Global Prevalence of Diabetes2004 · 15,358 citations
  3. 3Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes2003 · 208 citations
  4. 4Metformin revisited: re‐evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents2004 · 162 citations
  5. 5Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes2007 · 367 citations